Oblon, McClelland, Maier & Neustadt, L.L.P.
Method for treating cancer patients with severe renal impairment
A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m2/day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.
TAIHO PHARMACEUTICAL CO., LTD.
A A A A A A
A61P A61K A61P A61K A61K A61P
inventional inventional inventional inventional inventional inventional
Kenichiro
Yoshida